Tropical and Travel-Related Infections — Written Clinical Reasoning

SAQ 1 — Integrated Management of Severe Falciparum Malaria (20 marks, 30 minutes)

Prompt: Outline your integrated management plan for this patient with severe falciparum malaria, including: (a) how you confirm severity and the implications for triage; (b) the specific antimalarial regimen with exact drug, dose, route, timing, and rationale; (c) supportive care in the first 48 hours; (d) the complication you must monitor for over the subsequent four weeks and why; (e) the public health and follow-up considerations; and (f) the common exam trap in the diagnostic workup. [1]

Model Answer

(a) Confirm severity and triage (3 marks): [1]

This patient has severe falciparum malaria by multiple WHO criteria. She has impaired consciousness (GCS 13), jaundice (bilirubin above 50 micromol/L), hyperparasitaemia (9 per cent), metabolic acidosis (bicarbonate below 15, lactate above 5), renal impairment (creatinine above 265 by some thresholds; this patient is at 245 with oliguria likely), and a coagulopathy (INR 1.6). Any one of these mandates parenteral therapy. She is a returning traveller from sub-Saharan Africa who took incomplete prophylaxis — the GeoSentinel data show malaria is the most common specific diagnosis (21 per cent) in febrile returned travellers, and VFR travellers are the highest-risk group [1]. She needs immediate admission to a high-dependency or intensive care setting: she has cerebral malaria, AKI, metabolic acidosis, and is at risk of ARDS, seizures, hypoglycaemia, and further deterioration within hours. A single blood film has confirmed the diagnosis — the rule-out-malaria-first principle is satisfied and treatment must not be delayed.

(b) Antimalarial regimen — IV artesunate (4 marks): [1]

The treatment is intravenous artesunate 2.4 mg/kg at 0, 12, and 24 hours, then daily, until oral therapy is tolerated, followed by a full course of oral artemisinin-based combination therapy (ACT, e.g. artemether-lumefantrine). The SEAQUAMAT trial established IV artesunate as superior to IV quinine in adults, reducing mortality from 22 per cent to 15 per cent — a 34.7 per cent relative reduction [2]. AQUAMAT confirmed a 22.5 per cent mortality reduction in African children [3]. Artesunate is preferred over quinine because it is more rapidly parasiticidal, simpler to administer (no loading-dose calculation, no cardiac monitoring), and safer (quinine causes hypoglycaemia from insulin stimulation — especially dangerous in pregnancy and severe disease — and is cardiotoxic, requiring ECG monitoring). IV artesunate must be given immediately severe malaria is recognised; do not wait for a higher parasitaemia or further deterioration. The first dose is the most important intervention in this patient's whole admission.

(c) Supportive care in the first 48 hours (5 marks): [1]

1. Airway and breathing: she is drowsy (GCS 13) and tachypnoeic — monitor for deterioration in consciousness requiring intubation for airway protection. Monitor oxygen saturation; if ARDS develops (bilateral infiltrates, PaO2/FiO2 below 300), use lung-protective ventilation (tidal volume 6 mL/kg predicted body weight, plateau pressure below 30 cm water).
2. Glucose: hypoglycaemia is a major cause of death in severe malaria, both from the illness itself (impaired gluconeogenesis) and from quinine (insulin stimulation) — artesunate is safer but glucose must still be checked every 2 to 4 hours and treated with IV dextrose if below 2.2 mmol/L.
3. Fluids and renal: avoid aggressive fluid loading, which worsens pulmonary oedema and ARDS. Give cautious maintenance fluid; treat AKI supportively, with renal replacement therapy if indicated. Monitor urine output hourly.
4. Seizure prophylaxis and treatment: cerebral malaria carries a risk of seizures; treat with benzodiazepines. Do not routinely use prophylactic anticonvulsants.
5. Anaemia and transfusion: transfuse packed red cells for severe anaemia (haemoglobin below 70 g/L, or higher if there is physiological compromise), being cautious of volume overload. She is at 78 g/L with ongoing haemolysis — transfuse if she drops below 70 or if she develops respiratory compromise.
6. Acidosis: the acidosis reflects the severity of the infection and tissue hypoperfusion; it improves with parasite clearance and supportive care rather than with bicarbonate.
7. Avoid: corticosteroids (no benefit, possible harm in cerebral malaria), heparin (no role for DIC), and exchange transfusion (evidence limited; reserve for extreme parasitaemia above 10 per cent with organ dysfunction, in consultation). [1]

(d) The four-week complication — post-artesunate delayed haemolysis (4 marks): [1]

This is the trap after apparent recovery. Post-artesunate delayed haemolysis (PADH) occurs 1 to 4 weeks after artesunate treatment, via the pitting mechanism: the spleen expels the dead parasite from the infected erythrocyte and returns the once-infected pitted cell to the circulation; these cells have a shortened lifespan and haemolyse a week or more later. Jauréguiberry and colleagues showed that among non-transfused travellers treated with artesunate for severe malaria, 22 per cent developed delayed haemolysis, and that it is predictable from the early concentration of once-infected erythrocytes [4]. The practical implication: check the haemoglobin weekly for 4 weeks after artesunate in this non-immune traveller, so that a Coombs-negative haemolytic anaemia is anticipated rather than presenting as an undiagnosed late collapse. Patient and GP must be informed of this in the discharge summary.

(e) Public health and follow-up (2 marks): [1]

• Malaria is notifiable in Australia and most jurisdictions — notify the public health unit.
• Counsel the patient on incomplete prophylaxis as a contributor, and on the need for full adherence and bite avoidance for any future travel, recognising that immunity is not acquired from a single infection.
• Arrange outpatient review at 1 week (clinical, haemoglobin) and weekly for 4 weeks (haemoglobin for PADH), with a final review at 1 month.
• Screen for other travel-acquired infections if not already done (HIV, viral hepatitis, strongyloides serology — especially given her Kenyan exposure and the risk of hyperinfection if she ever needs steroids) [6].

(f) The exam trap in the diagnostic workup (2 marks): [1]

The cardinal trap — and the one the examiners will test — is accepting a single negative blood film as exclusion of malaria. Parasitaemia is cyclical, and in early or partially immune infection a single film can be negative even in genuine falciparum malaria. The rule is to repeat thick and thin films every 12 to 24 hours for at least three sets over 48 to 72 hours before accepting that malaria is excluded. In this patient the film was positive on the first set, so treatment was not delayed — but the principle stands, and the registrar who discharges a febrile returning traveller after one negative film has made the single most dangerous error in tropical medicine. A rapid diagnostic test (RDT) is a useful adjunct where microscopy is delayed, but it does not quantify parasitaemia (which drives severity assessment and monitoring) and can remain positive for weeks after treated infection. [1]